Tirzepatide (Zepbound®) for Chronic Weight Management in Adults With an Initial BMI of at Least 27 kg/m2 and Prediabetes
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for tirzepatide (Zepbound) for once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index (BMI) of equal to or greater than 27 kg/m2 and prediabetes.